Literature DB >> 32373972

Hsa_circ_0124055 and hsa_circ_0101622 regulate proliferation and apoptosis in thyroid cancer and serve as prognostic and diagnostic indicators.

J-W Sun1, S Qiu, J-Y Yang, X Chen, H-X Li.   

Abstract

OBJECTIVE: Recent studies have corroborated that circular RNAs (circRNAs) as endogenous noncoding RNAs gain research interest in carcinogenesis, functioning as prognostic and diagnostic biomarkers and therapeutic targets. The present study is aimed to determine whether circRNAs could serve as prognostic and diagnostic biomarkers to predict thyroid carcinoma.
MATERIALS AND METHODS: High-throughput sequencing analysis was conducted to detect circRNAs expression profile in thyroid cancer. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) measurement was utilized to validate circRNAs expression in blood and tissue specimens. Kaplan-Meier method and receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to assess whether circRNAs could function as prognostic and diagnostic biomarkers of thyroid cancer, respectively.
RESULTS: Hsa_circ_0124055 and hsa_circ_0101622 as the most conspicuous biomarkers were significantly increased in tumor tissues and plasma of thyroid cancer patients. High hsa_circ_0124055 or hsa_circ_0101622 expression exhibited shorter overall survival. Our findings also provided strong evidence that plasma hsa_circ_0124055 (AUC = 0.836, 95% CI: 0.763-0.908, p<0.001) and hsa_circ_0101622 (AUC = 0.805, 95% CI: 0.727-0.883, p<0.001) could be used as diagnostic markers for thyroid cancer, and hsa_circ_0124055 combined with hsa_circ_0101622 could provide a more powerful diagnostic value (AUC = 0.911, 95% CI: 0.859-0.962, p<0.001) than the use of hsa_circ_0124055 or hsa_circ_0101622 alone. Furthermore, the knockdown of hsa_circ_0124055 or hsa_circ_0101622 exhibited a significant anti-proliferative and pro-apoptotic activity of thyroid cancer cells in vivo and in vitro.
CONCLUSIONS: Both hsa_circ_0124055 and hsa_circ_0101622 could facilitate the prognosis and diagnosis of thyroid cancer, and function as the therapeutic targets for clinical practice.

Entities:  

Year:  2020        PMID: 32373972     DOI: 10.26355/eurrev_202004_21016

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Circular RNA circRNA_0000094 sponges microRNA-223-3p and up-regulate F-box and WD repeat domain containing 7 to restrain T cell acute lymphoblastic leukemia progression.

Authors:  Yan Hou; Junjie Sun; Jie Huang; Fengzhi Yao; Xuelian Chen; Bin Zhu; Dongchi Zhao
Journal:  Hum Cell       Date:  2021-03-06       Impact factor: 4.174

Review 2.  The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases.

Authors:  Yu Zhang; Dong-Dong Jia; Yi-Fei Zhang; Meng-Die Cheng; Wen-Xiu Zhu; Pei-Feng Li; Yin-Feng Zhang
Journal:  Int J Biol Sci       Date:  2021-04-17       Impact factor: 6.580

3.  circATP2A2 promotes osteosarcoma progression by upregulating MYH9.

Authors:  Xin Cao; Xianfeng Meng; Peng Fu; Lin Wu; Zhen Yang; Huijin Chen
Journal:  Open Med (Wars)       Date:  2021-11-22

Review 4.  Function and Clinical Significance of Circular RNAs in Thyroid Cancer.

Authors:  Xuelin Yao; Qiu Zhang
Journal:  Front Mol Biosci       Date:  2022-07-22

Review 5.  Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer.

Authors:  Milad Ashrafizadeh; Mohammad Reza Bakhoda; Zahra Bahmanpour; Khandan Ilkhani; Ali Zarrabi; Pooyan Makvandi; Haroon Khan; Samaneh Mazaheri; Maryam Darvish; Hamed Mirzaei
Journal:  Front Chem       Date:  2020-10-15       Impact factor: 5.221

Review 6.  CircRNAs: biogenesis, functions, and role in drug-resistant Tumours.

Authors:  Shuo Ma; Shan Kong; Feng Wang; Shaoqing Ju
Journal:  Mol Cancer       Date:  2020-08-05       Impact factor: 27.401

Review 7.  CircRNA: A novel potential strategy to treat thyroid cancer (Review).

Authors:  Guomao Zhu; Xingyu Chang; Yuchen Kang; Xinzhu Zhao; Xulei Tang; Chengxu Ma; Songbo Fu
Journal:  Int J Mol Med       Date:  2021-09-16       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.